LESOTHO-based cultivator and manufacturer of medical cannabis flower, extracts and oils known as MG Health have received official confirmation that their stringent manufacturing process is aligned with the European Union’s good manufacturing practice (GMP) standards.

This was announced by MG Health Chief Executive Officer, Andre Bothma at a media briefing in Maseru on Thursday.
The confirmation he said makes MG Health the first manufacturer in Africa to be able to export medical cannabis flower as an Active Pharmaceutical Ingredient (API) to the EU market out of less than 20 companies worldwide, having achieved this certificate of trust.
Mr Bothma said the GMP guidelines state that the minimum requirements that a manufacturer must meet include ensuring that their products consistently maintain high quality, from batch to batch for their intended use.
He also said effectively opening up global medical markets for the company, alignment with GMP standards will give doctors the certainty they require that the product they are prescribing to their patients is consistent of a high quality, safe and effective.
The recent confirmation of EU GMP compliance for MG Health he said was granted by the government of the Upper Bavaria district in Germany after a request for import was made by Drapalin Pharmaceuticals, the strategic partner of MG Health in Germany.